EverHint Lens - Organon & Co. ($OGN) - Yahoo Top Gainer (+24%) Stock Analysis - April 10, 2026

Analysis Date: 2026-04-10
Sector: Healthcare
Industry: Drug Manufacturers - General
Exchange: NYSE

Executive Summary

Organon & Co. is currently trading at $8.56 (🟢 +23.95% today) with a market capitalization of $2.23B.

Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio.

Price & Valuation

Current Price: $8.56 (at 12:16 PM ET)
Current Volume: 25.6M
Day Range: $7.92 - $8.89
52-Week Range: $5.69 - $13.24
P/E Ratio: 11.92

DCF Valuation: Undervalued

• Intrinsic Value (Unlevered DCF): $48.84
• Current Price: $8.56
• Discount/Premium: +470.2%

Levered DCF: $33.12 (+286.7%)

⚠️ High divergence between levered and unlevered DCF
⚠️ DCF shows extreme valuation gap (>100%)

DCF analysis suggests the stock may be trading at a 470.2% discount to its intrinsic value.

DCF values calculated as of 2026-04-10. Underlying assumptions are not disclosed by the data provider. Levered vs unlevered can diverge materially for highly levered companies.

Market Context

Major Indices:

• S&P 500: $6823.70 (🔴 -0.01%)
• NASDAQ Composite: $22907.01 (🟢 +0.37%)
• Dow Jones Industrial Average: $47965.68 (🔴 -0.46%)

Peer Comparison

Peer comparison (11 companies):

• OGN - Organon & Co. ($8.56, +24.0%, $2.23B) ← Current
• GRDN - Guardian Pharmacy Services, Inc. ($39.28, -3.4%, $2.49B)
• PAHC - Phibro Animal Health Corporation ($57.91, -2.0%, $2.35B)
• AVDL - Avadel Pharmaceuticals plc ($21.64, 0.0%, $2.12B)
• AUPH - Aurinia Pharmaceuticals Inc. ($15.64, -2.0%, $2.08B)
• SEM - Select Medical Holdings Corporation ($16.39, +0.1%, $2.03B)
• MD - Pediatrix Medical Group, Inc. ($21.40, +0.3%, $1.78B)
• HRMY - Harmony Biosciences Holdings, Inc. ($28.94, -0.8%, $1.67B)
• NUVB - Nuvation Bio Inc. ($4.43, -4.4%, $1.53B)
• ALVO - Alvotech ($3.62, +0.7%, $1.13B)
• TLRY - Tilray Brands, Inc. ($6.62, -1.6%, $771M)

Financial Performance

Latest Quarter (2025-12-31):

• Revenue: $1.51B
• Net Income: $-205.00M
• EPS: $-0.79
• Revenue Growth (QoQ): -5.9%

Dividend Analysis

Dividend Status: Active dividend-paying stock

Latest Dividend:

• Amount: $0.02 per share
• Ex-Dividend Date: 2026-02-23
• Payment Date: 2026-03-12
  Annual Metrics:
• Annual Dividend (TTM): $0.08
• Dividend Yield: 0.93%
• Payment Frequency: Quarterly
• Payment History: 19 dividend payments tracked

Consistency: OGN has a consistent quarterly dividend payment history.

Earnings Calendar

Next Earnings Report: 2026-05-07 (Before Market Open)

• EPS Estimate: $0.84
• Revenue Estimate: $1.50B

Most Recent Report: 2026-02-12

• EPS: $0.63 (Est: $0.73) ✗ Miss
• Revenue: $1.51B

Historical Data: 25 earnings events tracked

Analyst Outlook

Analyst Price Target Consensus:

• Target: $6.50 (-24.1% upside)
• Range: $5.00 - $8.00
• Median: $6.50

Next Quarter Estimates (2027-12-31):

• Revenue: $1.56B
• EPS: $0.71

Analyst Consensus

Overall Rating: Buy

Rating Distribution (47 total ratings):

• 🟢 Buy/Outperform: 12 (25.5%)
• ⚪ Hold/Neutral: 8 (17.0%)
• 🔴 Sell/Underperform: 5 (10.6%)

Recent Analyst Actions:

• Barclays (2025-12-08): Initiate Underweight
• Piper Sandler (2025-10-27): Downgrade Overweight → Underweight
• Exane BNP Paribas (2026-04-10): Maintain Outperform
• Barclays (2026-02-24): Maintain Underweight
• Piper Sandler (2025-05-15): Maintain Overweight

Consensus based on 47 analyst ratings from major financial institutions

Trading Signals

Our technical analysis identified 2 trading signal(s) in the last 60 days:

• 2026-02-25: Sma20 Sma50 - SMA20_x_SMA50_Sell @ $7.51
• 2026-02-10: Ema10 Ema30 - EMA10_x_EMA30_Sell @ $7.81

Insider Activity

Recent Transactions (Last 10):

• Buys: 5
• Sells: 5

Notable Transactions:

• 2026-03-31: Drinane Juliana Papa - Buy (Award, 125,208 shares)
• 2026-03-31: Drinane Juliana Papa - Buy (Option Exercise, 10,073 shares)
• 2026-03-31: Drinane Juliana Papa - Sell (Tax Withholding, 3,451 shares @ $5.70)

Congressional Trading Activity

Tracking recent stock transactions by U.S. Congress members

House of Representatives: 30 transactions tracked

Recent Activity:

• 🔴 Ro Khanna (CA17): Sale on 2023-11-03 @ $13.30, Amount: $1,001 - $15,000
• 🟢 Ro Khanna (CA17): Purchase on 2023-10-02 @ $16.69, Amount: $1,001 - $15,000
• 🔴 Ro Khanna (CA17): Sale on 2023-07-28 @ $22.18, Amount: $1,001 - $15,000
• 🟢 Ro Khanna (CA17): Purchase on 2023-06-29 @ $20.73, Amount: $1,001 - $15,000
• 🔴 Ro Khanna (CA17): Sale on 2023-05-19 @ $20.43, Amount: $1,001 - $15,000

U.S. Senate: 4 transactions tracked

Recent Activity:

• 🔴 Gary Peters: Sale on 2025-10-07 @ $10.60, Amount: $1,001 - $15,000
• ⚪ Gary Peters: Sale (Full) on 2025-07-10 @ $10.02, Amount: $1,001 - $15,000
• ⚪ John W. Hickenlooper: Sale (Full) on 2021-06-28, Amount: $1,001 - $15,000
• ⚪ John W. Hickenlooper: Sale (Full) on 2021-06-28, Amount: $1,001 - $15,000

Congressional trading data sourced from official disclosure filings

News Sentiment Analysis

AI Analysis (based on 30 recent articles):

Recent headlines show strongly positive sentiment for Organon & Co. (OGN) driven by reports of Sun Pharma nearing a takeover offer, boosting shares 15% and attracting investor attention. Positive developments include VTAMA clinical data and new licensing deals, though earlier Q4 earnings misses and stock declines temper the outlook. Overall, takeover buzz dominates, signaling potential upside.

Key Themes:

• Takeover Rumors
• Product Advancements
• Earnings Weakness

Sentiment: Positive (88% confidence)

Reddit Sentiment

Community Discussion (last 30 days from r/wallstreetbets, r/stocks, r/investing):

Overall Sentiment: Strongly Bearish 📉📉 (Score: -0.527)

Post Analysis:

• Total posts: 1
• Bullish: 0 (0.0%)
• Bearish: 1 (100.0%)
• Neutral: 0 (0.0%)
• Total engagement: 6 (upvotes + comments)

Note: Sentiment score ranges from -1.0 (very bearish) to +1.0 (very bullish), weighted by post engagement.

Recent News

5 most recent articles covering OGN:

• Sun Pharma Nears Final Offer For Organon In Largest Overseas Bet (benzinga.com, 2026-04-10) — Read more
• Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know (zacks.com, 2026-04-10) — Read more
• This Women's Healthcare Stock Is Up 15% on Reports of a Takeover In the Works (investopedia.com, 2026-04-10) — Read more
• These Stocks Are Today's Movers: Nvidia, Intel, Lumentum, Coherent, Organon, and More. (barrons.com, 2026-04-10) — Read more
• Head-To-Head Analysis: XWELL (NASDAQ:XWEL) & Organon & Co. (NYSE:OGN) (defenseworld.net, 2026-04-10) — Read more

Full news analysis based on 30 recent articles

Generated by Everhint Lens - Quantitative Stock Analysis
Last updated: 2026-04-10 09:16:17 AM PDT

Disclaimer: This is not investment advice. Always do your own research before making investment decisions.